Stoke Therapeutics (STOK) Cash & Equivalents (2018 - 2026)

Stoke Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $155.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 43.36% year-over-year to $155.7 million; the TTM figure through Mar 2026 stood at $155.7 million (down 43.36% YoY), while the FY2025 annual figure was $84.2 million, down 34.19% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $155.7 million, up from $84.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $274.8 million in Q1 2025, with the low at $67.8 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $150.0 million (2024), against an average of $146.6 million.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 68.56% in 2022, then soared 183.47% in 2023.
• Stoke Therapeutics' Cash & Equivalents stood at $113.6 million in 2022, then surged by 68.59% to $191.4 million in 2023, then tumbled by 33.15% to $128.0 million in 2024, then plunged by 34.19% to $84.2 million in 2025, then jumped by 84.82% to $155.7 million in 2026.
• Business Quant data shows STOK's Cash & Equivalents at $155.7 million in Q1 2026, $84.2 million in Q4 2025, and $83.4 million in Q3 2025.